Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics Inc. (LCTX) is a clinical-stage biotechnology leader developing novel cell-based therapies for degenerative diseases. This dedicated news hub provides investors and stakeholders with timely updates on corporate developments, clinical research progress, and regulatory milestones.
Access authoritative information about LCTX's innovative platforms in cell replacement therapies and targeted drug delivery systems. Our curated collection features press releases covering clinical trial results, strategic partnerships, intellectual property updates, and scientific presentations.
Stay informed about advancements in treatments for retinal degeneration, spinal cord injuries, and oncology applications. All content is verified at source, ensuring reliable tracking of the company's progress in regenerative medicine. Bookmark this page for streamlined access to essential updates impacting LCTX's position in the biotech sector.
Lineage Cell Therapeutics (NYSE American: LCTX) has launched a new islet cell transplant program targeting Type 1 Diabetes (T1D). The company's primary focus is addressing the manufacturing scale challenges in islet cell production, aiming to establish a dynamic culturing system that can support large-scale production.
CEO Brian M. Culley highlighted that while several islet cell programs have reached Phase 1 clinical trials, the industry faces significant challenges in manufacturing sufficient material for the addressable patient population. The company plans to leverage its GMP manufacturing capabilities to develop a production system capable of generating hundreds of millions of cells per patient.
The initiative will begin with testing their proprietary cell line, marking their third unique master cell bank at their in-house facility. Future plans include demonstrating system compatibility with hypo-immune cell lines for clinical T1D applications.
Lineage Cell Therapeutics (NYSE:LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies for neurological and ophthalmic conditions, has announced upcoming investor conference presentations.
CEO Brian M. Culley will present at two major healthcare conferences: the H.C. Wainwright Global Investment Conference on September 8, 2025, at 11:30am ET, and Baird's Global Healthcare Conference on September 9, 2025, at 12:50pm ET. A replay of the H.C. Wainwright presentation will be available on the company's website after the event.
Lineage Cell Therapeutics (NYSE American: LCTX) has entered into a significant research collaboration with William Demant Invest A/S (WDI) to develop ReSonance™ (ANP1), a novel cell therapy for hearing loss. The partnership includes up to $12 million in funding from WDI over a three-year term to advance preclinical development.
The collaboration will combine Lineage's cell manufacturing expertise with hearing loss research from Eriksholm Research Centre. The development activities will cover cell manufacturing, proof-of-concept studies, delivery development, and regulatory strategy to support potential IND/CTA filing.
ReSonance represents Lineage's first internally-developed cell transplant program, targeting auditory nerve cell restoration for the 2.5 billion people expected to experience hearing loss by 2025. The therapy aims to treat auditory neuropathy by replacing damaged auditory nerve cells to restore hearing and potentially enhance cochlear implant effectiveness.
Lineage Cell Therapeutics (NYSE:LCTX) reported Q2 2025 financial results and significant clinical progress. The company highlighted positive 36-month results from the OpRegen Phase 1/2a trial, showing sustained benefits in treating geographic atrophy, with treated patients demonstrating a mean improvement of +6.2 letters in vision acuity.
Key financial metrics include $42.3 million in cash reserves supporting operations into Q1 2027, revenues of $2.8 million (up from $1.4M YoY), and a net loss of $30.5 million. The company achieved manufacturing milestones and treated its first chronic patient in the OPC1 spinal cord injury program.
The quarter was marked by a $14.8 million impairment charge related to the VAC platform and increased warrant liability expenses due to share price appreciation.Lineage Cell Therapeutics (NYSE American: LCTX), a clinical-stage biotechnology company focused on allogeneic cell therapies for neurological conditions, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after U.S. market close.
The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Investors can access the call by dialing (800) 715-9871 from the U.S. and Canada. A webcast replay will be available for 30 days, and a telephone replay through August 19, 2025, can be accessed using conference ID 7788342.
Lineage Cell Therapeutics (NYSE:LCTX) has announced a significant milestone in its DOSED clinical study with the first-ever treatment of a chronic spinal cord injury patient using OPC1 cells and a new parenchymal spinal delivery system at UC San Diego Health.
The study will evaluate both subacute (21-42 days post-injury) and chronic (1-5 years post-injury) spinal cord injury patients. The first patient, with a complete SCI injury (AIS grade A), successfully received a one-time injection of 10 million OPC1 cells. OPC1, an allogeneic stem cell-derived cell transplant, aims to restore or enhance functional activity in SCI patients by replacing damaged cells.
The treatment builds on extensive safety data from two previous clinical trials, including a 5-patient Phase 1 trial with 13+ years of follow-up and a 25-patient Phase 1/2a trial with 7+ years of monitoring, both showing no unexpected serious adverse events.
Lineage Cell Therapeutics (LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies, announced its participation in the 3rd Annual H.C. Wainwright BioConnect Investor Conference. CEO Brian M. Culley will engage in a fireside chat with Joseph Pantginis, Managing Director of Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The event will be held at the Nasdaq stock exchange headquarters in New York. Investors can schedule meetings with management through H.C. Wainwright representatives, and a replay of the fireside chat will be available on Lineage's website after the conference.
Lineage Cell Therapeutics (NYSE: LCTX) reported its Q1 2025 financial results and business updates. The company's cash position of $47.9 million is expected to support operations into Q1 2027. Q1 2025 financial highlights include revenues of $1.5 million and a net loss of $4.1 million ($0.02 per share).
Key developments include upcoming 36-month results presentation for RG6501 (OpRegen) Phase 1/2a study at Clinical Trials Summit 2025, initiation of the DOSED clinical study for OPC1 in spinal cord injury patients, and announcement of the 3rd Annual SCI Investor Symposium. The company continues its collaboration with Roche and Genentech on the GAlette Study for geographic atrophy treatment.
Operating expenses were $8.0 million, with R&D expenses at $3.1 million and G&A expenses at $4.9 million.FAQ
What is the current stock price of Lineage Cell The (LCTX)?
What is the market cap of Lineage Cell The (LCTX)?
